Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

@article{dePauw2008RevisedDO,
  title={Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.},
  author={Ben E. de Pauw and Thomas J. Walsh and J Peter Donnelly and David A. Stevens and John E. Edwards and Thierry Calandra and Peter G. Pappas and Johan Maertens and Olivier Lortholary and Carol A. Kauffman and David W. Denning and Thomas F. Patterson and Georg Maschmeyer and Jacques Bill{\'e} and William E. Dismukes and Raoul Herbrecht and William W. Hope and Christopher C. Kibbler and B J Kullberg and Kieren A. Marr and Patricia Mu{\~n}oz and Frank C. Odds and John R. Perfect and {\'A}ngela Restrepo and Markus Ruhnke and Brahm H. Segal and Jack D. Sobel and Tania C. Sorrell and Claudio Viscoli and John R. Wingard and Theoklis E. Zaoutis and John E. Bennett},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2008},
  volume={46 12},
  pages={
          1813-21
        }
}
  • B. D. de PauwT. Walsh J. Bennett
  • Published 15 June 2008
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
BACKGROUND Invasive fungal diseases are important causes of morbidity and mortality. [] Key Method The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved.

Tables from this paper

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

  • J. DonnellyS. Chen P. Pappas
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

  • B. SegalR. Herbrecht B. D. de Pauw
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
An expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes.

European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.

Host factors according to revised EORTC/MSG criteria were significantly associated with the development of IFI/IMI in patients in this case-control study.

Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology

These proposed definitions of breakthrough IFI are intended to support the design of future clinical trials and epidemiological research in clinical mycology, with the ultimate goal of increasing the comparability of clinical trial results.

Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)

Since the last edition of Diagnosis of Invasive Fungal Diseases recommendations of the German Society for Hematology and Oncology in 2012, integrated care pathways have been proposed for the management and therapy of IFDs with either a diagnostic driven strategy as opposed to a clinical or empirical driven strategy.

Advances and Prospects for Molecular Diagnostics of Fungal Infections

  • S. Bretagne
  • Medicine, Biology
    Current infectious disease reports
  • 2010
A checklist of items has been proposed to improve the reliability of the results and clinicians’ confidence in them, with emphasis on limiting false-positive results from contamination with either previously amplified products or environmental commensals.

Improving outcome of fungal diseases – Guiding experts and patients towards excellence

Three initiatives launched by the European Confederation of Medical Mycology aim at improving outcome of fungal diseases through guiding experts and patients towards excellence, and acknowledge fungal infections as a global problem.

Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis.

It is concluded that the 2008 EORTC/MSG revised definitions reduced the number of cases classified as 'possible' IA, but additionally, there has been a dramatic reduction in 'probable' cases.

FungiScope™—Global Emerging Fungal Infection Registry

The structure and management of the FungiScope™ registry is described, which is an appropriate method of pooling the scarce and scattered information for researching rare IFD.
...

References

SHOWING 1-10 OF 35 REFERENCES

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

  • S. AşçıoğluJ. Rex T. Walsh
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2002
During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantial

Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates

A high number of pulmonary infiltrates would be diagnosed as IPA, but only a diagnosis of “proven/probable” IPA should be considered reliable in the clinical management of suspected IPA.

b - d -Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome

The Glucatell serum BG detection assay is highly sensitive and specific as a diagnostic adjunct for IFI and has a 100% negative predictive value.

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

BACKGROUND Measurement of (1-->3)-beta-D-Glucan (BG) has emerged as an adjunct diagnostic strategy for invasive fungal infections (IFI). METHODS Subjects at 6 clinical sites in the United States

Laboratory diagnosis of invasive aspergillosis.

Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey.

  • A. CornilletC. Camus J. Gangneux
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
This survey at a whole institution underlines the high number of cases of invasive aspergillosis among nonneutropenic patients, with an overall mortality rate that was significantly higher than that for neutropenia patients.

Invasive aspergillosis in the intensive care unit.

Because of a delay in the diagnosis of IA, the mortality rate exceeds 50%.

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD and was superior in preventing invasive aspergillosis and reducing the rate of deaths related toFungal infections.

Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes

It is confirmed that mortality from invasive aspergillosis in severely immunosuppressed patients remains high even with standard amphotericin B, and new approaches and new therapies are needed to improve the outcome.

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazoles prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival.